<DOC>
	<DOCNO>NCT02415959</DOCNO>
	<brief_summary>The objective study assess efficacy safety different dos Creon Immediate Release ( IR ) comparison Creon® 25,000 Delayed Release/Gastro-Resistant ( DR/GR ) subject Pancreatic Exocrine Insufficiency ( PEI ) due Cystis Fibrosis ( CF ) .</brief_summary>
	<brief_title>Efficacy Safety Study Creon IR Subjects With Pancreatic Exocrine Insufficiency Due Cystic Fibrosis</brief_title>
	<detailed_description>This study Phase II , randomize , parallel-group , active-controlled , double-blind , dose ranging , multicenter study 4 different dos Creon IR one dose active control Creon® ( DR/GR ) , administer subject 12 year old PEI due CF . The study divide two period : screening period 14 day double-blind treatment period 6 7 day .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>1 . Subject voluntarily sign date Informed Consent Form ( ICF ) . For subject age less 18 year , parent , legally acceptable representative , must sign consent , require Independent Ethics Committee ( IEC ) , assent give subject . 2 . Subject 12 year old old time consent signature . 3 . Subject diagnosis CF previously confirm : sweat chloride test &gt; equal 60 mmol/Ls and/or two CF cause Cystic Fibrosis trans membrane conductance regulator ( CFTR ) mutation CF clinical feature 4 . Subject document clinically confirm diagnosis pancreatic exocrine insufficiency . 5 . Subject human fecal elastase &lt; 100 µg/g stool screen 6 . Subject PEI currently clinically control ( clinically overt steatorrhea diarrhea ) treatment commercially available Pancreatic enzyme Replacement Therapy ( PERT ) , individually establish dose regimen 3 month , daily dose exceed 10,000 U lipase/kg/day . 7 . Females childbearing potential sexually active men agree continue use medically acceptable method birth control throughout study 7 day immediately last dose study drug . Medically acceptable method birth control include bilateral tubal ligation use either contraceptive implant , contraceptive injection ( e.g. , Depo Provera™ ) , intrauterine device , oral contraceptive take continually within past three month subject agrees continue use study adopt another birth control method , doublebarrier method consist combination two following : diaphragm , cervical cap , condom , spermicide . 1 . Subject &lt; 18 year age Body Mass Index ( BMI ) ZScore 1.5 ( minus 1.5 ) 2 . Subject history follow gastrointestinal disorder : pancreatitis within 6 month prior study entry ; fibrosing colonopathy ; distal ileal obstruction syndrome ( DIOS ) within 6 month prior study entry ; celiac disease ; gastric bypass partial/total gastrectomy ; Crohn 's disease ; small bowel surgery ( minor resection due meconium ileus without result malabsorption syndrome ) . Any type malignancy involve digestive tract last 5 year . 3 . Subjects diabetes mellitus , study specific dietary requirement may appropriate . 4 . Subject history endocrine respiratory ( except mild asthma ) medical illness nonrelated CF , might limit participation completion study . 5 . Subject history clinically significant neurological , cardiac , renal , hepatic ( include Hepatitis B C ) , hematologic psychiatric disease disorder , uncontrolled medical illness ( except cystic fibrosis ) might limit participation completion study . 6 . Subjects require concomitant treatment medication allow protocol expect need . 7 . Subjects require Nasogastric , Gtubes Jtubes . 8 . Subject currently participate interventional clinical study take experimental drug within 30 day prior Screening . 9 . Subject know HIVpositive . 10 . Subject history allergic reaction significant sensitivity pancreatin inactive ingredient ( excipients ) Creon® ( DR/GR ) Creon IR</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
</DOC>